Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

Table 4 Primary and secondary targets 12 weeks after treatment with rosuvastatin or rosuvastatin plus ezetimibe

	Primary Targets				Secondary Targets
	LDL-C ≤2.0 mmol/L	50 % reduction in LDL	ApoB ≤0.80 g/L	non-HDL-C ≤2.6	TG <1.7 mmol/L	ApoB:ApoA1 ratio <0.80	hsCRP <2 mg/L
Rosuvastatin 20 mg	2.07	19 % reduction	0.88	3.25	2.88	0.60	1.72
Rosuvastatin 10 mg + Ezetimibe 10 mg	2.12	24 % reduction	0.89	3.06	1.92	0.55	5.19

LDL-C, low-density lipoprotein cholesterol; apoB, apolipoprotein B;; non-HDL-C, non- high-density lipoprotein cholesterol; TG, triglycerides; apoA1, apolipoprotein A1; hsCRP, high-sensitivity C-reactive protein

ISSN: 1476-511X